EN“Non-Hodgkin lymphoma” sounds like a diagnosis, but it is more like the name of a large district: dozens of different diseases live under it, from those that must be treated this week to those that are simply watched for years.
That is why non-Hodgkin lymphoma treatment in Germany starts with the exact subtype. Below: why it comes first, which tests establish it, how aggressive and indolent lymphomas are approached, what happens at relapse and what is arranged for patients from abroad. An overview of all lymphomas: lymphoma treatment in Germany.
Why non-Hodgkin lymphoma is not one diagnosis
The name covers different tumours of lymphocytes, cells of the immune system, so lymphoma can grow in lymph nodes, spleen, bone marrow, stomach or skin and shows itself differently: a painless swollen node in the neck for one patient, night sweats, fever and weight loss for another, a chance finding on an unrelated scan for a third.
The main division runs not by stage but by pace and cell of origin: B-cell or T-cell, aggressive (fast growing) or indolent, that is slow. Diffuse large B-cell lymphoma and follicular lymphoma are neighbours by name and opposites by behaviour.
For the patient, “you have lymphoma” without a subtype says nothing about the approach or the outlook, so a German haematologist starts not with prescriptions but with a review of the tissue. The German haematologists’ guideline on diffuse large B-cell lymphoma (in German) shows why: it separates this lymphoma from similar ones treated differently.
What is established before treatment starts
Before treatment, the subtype is established from a whole removed lymph node or a sufficient piece of tissue, not from a needle aspirate: the pathologist must see how cells are arranged, not single cells. Slides and paraffin blocks from home are reviewed by a reference pathologist, a lymphoma specialist — one of the few situations where review genuinely changes the diagnosis rather than confirming it as a formality. How tissue is taken: biopsy in Germany.
Immunohistochemistry and molecular tests are added — in effect the tumour’s passport: which markers sit on the cell surface and whether genes are rearranged. This decides whether antibodies against CD20 and other targeted drugs join the regimen.
The stage is determined by PET-CT, not ultrasound, with a bone marrow aspiration where indicated. Before drug therapy come blood tests and checks of the heart and kidneys; hepatitis B and C and HIV are tested separately, because supportive treatment depends on them. More on the scan: PET-CT in Germany.
Aggressive and indolent lymphomas: two different logics
An aggressive lymphoma is treated at once, an indolent one that causes no trouble may first be watched. With an aggressive lymphoma the aim is to clear the disease completely: chemotherapy plus an antibody over a fixed number of cycles, an interim PET-CT, and radiotherapy to an initially bulky site where needed. Here a pause is more dangerous than haste.
With an indolent lymphoma it is the other way round: if the disease causes no trouble and blood counts are calm, a German centre may propose watchful waiting — regular examinations and tests without treatment. For a patient who has travelled far expecting “do something today”, this is the hardest recommendation to accept, yet watching is not a refusal of help: in advanced follicular lymphoma without symptoms, early treatment does not prolong life, and therapy starts once the disease causes symptoms, falling blood counts, rapid growth or pressure on organs.
Some subtypes fit neither logic: a gastric lymphoma linked to the bacterium Helicobacter pylori responds in some patients to antibiotics against it, and lymphomas of the nervous system have their own regimens. Drugs, cycles and tolerability: chemotherapy for lymphoma.
If the lymphoma returns
A relapse does not mean starting from zero: tissue is taken again first, because the subtype can change (an indolent lymphoma can turn aggressive), and then the tumour board chooses a second-line regimen. Afterwards, high-dose chemotherapy with a return of the patient’s own stem cells is discussed for some, a donor (allogeneic) transplant for others; see bone marrow transplant in Germany.
Where standard lines are exhausted, German centres discuss bispecific antibodies, which link immune cells to tumour cells, and CAR-T — therapy with the patient’s own T-lymphocytes reprogrammed in the laboratory. In diffuse large B-cell lymphoma that resisted first treatment or returned within a year after it, CAR-T is already a second-line standard for suitable patients. It is not available for every subtype or in every hospital, and the decision is always made by the centre, not by a web page. More: CAR-T therapy in Germany.
Frequently asked questions
Can treatment in Germany start with a diagnosis made at home?
Yes, after a check: a reference pathologist reviews the slides and blocks you bring, repeating stains or molecular tests if necessary, and a new biopsy follows if the material is insufficient. Only then is a plan proposed, since the subtype decides whether and how to treat.
Is it safe to watch an indolent lymphoma without treatment?
When there is no indication for treatment, watchful waiting is an accepted strategy, not negligence: in advanced follicular lymphoma without symptoms, early therapy does not prolong life. Watching means regular examinations and tests; treatment starts when symptoms appear, counts worsen or nodes grow quickly, so check-ups matter.
Is a new biopsy needed if the lymphoma returns?
As a rule, yes: German guidelines advise taking tissue again at relapse, because the lymphoma may have changed, for example from indolent to aggressive, which is treated differently. The most active site can be located beforehand on PET-CT; only then is second-line treatment chosen.
How AlenMed arranges treatment for non-Hodgkin lymphoma
AlenMed starts with the documents: histology slides and blocks, the pathologist’s report, images as files, blood results and discharge letters go to a haematology department, whose doctor says whether the material needs review, which tests must be repeated and how long the first stage takes. Then: a written estimate, a visa invitation, an interpreter at appointments and at the tumour board, a place for a companion. Among AlenMed’s partners is the Rotkreuzklinikum in Munich, where Prof. Marcus Hentrich, whose main subject is malignant lymphomas, heads the department of haematology and oncology and the Centre for Haematological Neoplasms.
Plan ahead: bring the biopsy material itself, not only the report; allow time between the histology review and the first cycle; ask for a written plan with follow-up dates and have the final discharge letter translated for your doctor at home.
This material is for information only and is not an offer. Treatment is decided by a doctor at an in-person consultation.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
